Table 6.
WSS95 comparison with the Cohen and Matwin systems across 15 SR topics.
| SR report topic | Cohen 2006 [7] (VPa) |
Cohen 2008 [12] (SVMb) |
Matwin 2010 [15] (FCNB/WEc) |
Our study (TI+AB+PT) |
| ACE inhibitors | 56.61 | 73.30 | 52.30 | 74.29 |
| ADHD | 67.95 | 52.60 | 62.20 | 67.92 |
| Antihistamines | 0 | 23.60 | 14.90 | 24.52 |
| Atypical antipsychotics | 14.11 | 17.00 | 20.60 | 17.95 |
| Beta blockers | 28.44 | 46.50 | 36.70 | 65.01 |
| Calcium channel blockers | 12.21 | 43.00 | 23.40 | 17.32 |
| Estrogens | 18.34 | 41.40 | 37.50 | 22.55 |
| NSAIDS | 49.67 | 67.20 | 52.80 | 77.35 |
| Opioids | 13.32 | 36.40 | 55.40 | 8.98 |
| Oral hypoglycemics | 8.96 | 13.60 | 8.50 | 13.52 |
| Proton pump inhibitors | 27.68 | 32.80 | 22.90 | 19.65 |
| Skeletal muscle relaxants | 0 | 37.40 | 26.50 | 58.55 |
| Statins | 24.71 | 49.10 | 31.50 | 27.80 |
| Triptans | 3.37 | 34.60 | 27.40 | 39.64 |
| Urinary incontinence | 26.14 | 43.20 | 29.60 | 20.80 |
| Average | 23.43 | 40.80 | 33.50 | 37.06 |
aVP: voting Perceptron-based automated citation classification system
bFCNB/WE: factorized complement naïve Bayes with weight engineering
cSVM: support vector machine